Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
Background Evaluating COVID-19 vaccine effectiveness (VE) domestically is crucial for assessing and determining national vaccination policy. This study aimed to evaluate VE of mRNA COVID-19 vaccines in Japan. Methods We conducted a multicenter test-negative case-control study. The study comprised in...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14760584.2023.2188950 |
| _version_ | 1797680383292080128 |
|---|---|
| author | Haruka Maeda Nobuo Saito Ataru Igarashi Masayuki Ishida Mayumi Terada Takayasu Ito Hideko Ikeda Hiroshi Kamura Iori Motohashi Yuya Kimura Masaru Komino Hiromi Arai Osamu Kuwamitsu Nobuhiro Akuzawa Eiichiro Sando Toru Morikawa Haruki Imura Hiroki Inoue Tomoichiro Hayakawa Osamu Teshigahara Yasuji Ohara Motoi Suzuki Konosuke Morimoto |
| author_facet | Haruka Maeda Nobuo Saito Ataru Igarashi Masayuki Ishida Mayumi Terada Takayasu Ito Hideko Ikeda Hiroshi Kamura Iori Motohashi Yuya Kimura Masaru Komino Hiromi Arai Osamu Kuwamitsu Nobuhiro Akuzawa Eiichiro Sando Toru Morikawa Haruki Imura Hiroki Inoue Tomoichiro Hayakawa Osamu Teshigahara Yasuji Ohara Motoi Suzuki Konosuke Morimoto |
| author_sort | Haruka Maeda |
| collection | DOAJ |
| description | Background Evaluating COVID-19 vaccine effectiveness (VE) domestically is crucial for assessing and determining national vaccination policy. This study aimed to evaluate VE of mRNA COVID-19 vaccines in Japan. Methods We conducted a multicenter test-negative case-control study. The study comprised individuals aged ≥16 visiting medical facilities with COVID-19-related signs or symptoms from 1 January to 26 June 2022, when Omicron BA.1 and BA.2 were dominant nationwide. We evaluated VE of primary and booster vaccination against symptomatic SARS-CoV-2 infections and relative VE of booster compared with primary. Results We enrolled 7,931 episodes, including 3,055 test positive. The median age was 39, 48.0% were male, and 20.5% had underlying medical conditions. In individuals aged 16 to 64, VE of primary vaccination within 90 days was 35.6% (95% CI, 19.0–48.8%). After booster, VE increased to 68.7% (60.6–75.1%). In individuals aged ≥65, VE of primary and booster was 31.2% (−44.0–67.1%) and 76.5% (46.7–89.7%), respectively. Relative VE of booster compared with primary vaccination was 52.9% (41.0–62.5%) in individuals aged 16 to 64 and 65.9% (35.7–81.9%) in individuals aged ≥65. Conclusions During BA.1 and BA.2 epidemic in Japan, mRNA COVID-19 primary vaccination provided modest protection. Booster vaccination was necessary to protect against symptomatic infections. |
| first_indexed | 2024-03-11T23:29:11Z |
| format | Article |
| id | doaj.art-c5e2c260b54845e1b8297de267718e84 |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-11T23:29:11Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-c5e2c260b54845e1b8297de267718e842023-09-20T10:33:43ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952023-12-0122128829810.1080/14760584.2023.21889502188950Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)Haruka Maeda0Nobuo Saito1Ataru Igarashi2Masayuki Ishida3Mayumi Terada4Takayasu Ito5Hideko Ikeda6Hiroshi Kamura7Iori Motohashi8Yuya Kimura9Masaru Komino10Hiromi Arai11Osamu Kuwamitsu12Nobuhiro Akuzawa13Eiichiro Sando14Toru Morikawa15Haruki Imura16Hiroki Inoue17Tomoichiro Hayakawa18Osamu Teshigahara19Yasuji Ohara20Motoi Suzuki21Konosuke Morimoto22Institute of Tropical Medicine, Nagasaki UniversityOita UniversityYokohama City University School of MedicineChikamori HospitalNijigaoka HospitalToyota Kosei HospitalToyota Kosei HospitalLoco Clinic NakameguroKawasaki Municipal Tama HospitalSaiseikai Kazo HospitalSaiseikai Kazo HospitalSaiseikai Kazo HospitalGohongi ClinicGunma Chuo HospitalKita-Fukushima Medical CenterNara City HospitalRakuwakai Otowa HospitalRakuwakai Otowa HospitalHayakawa Internal Medicine ClinicMizuho Street ClinicTakagi HospitalInfectious Disease Surveillance Center, National Institute of Infectious DiseasesInstitute of Tropical Medicine, Nagasaki UniversityBackground Evaluating COVID-19 vaccine effectiveness (VE) domestically is crucial for assessing and determining national vaccination policy. This study aimed to evaluate VE of mRNA COVID-19 vaccines in Japan. Methods We conducted a multicenter test-negative case-control study. The study comprised individuals aged ≥16 visiting medical facilities with COVID-19-related signs or symptoms from 1 January to 26 June 2022, when Omicron BA.1 and BA.2 were dominant nationwide. We evaluated VE of primary and booster vaccination against symptomatic SARS-CoV-2 infections and relative VE of booster compared with primary. Results We enrolled 7,931 episodes, including 3,055 test positive. The median age was 39, 48.0% were male, and 20.5% had underlying medical conditions. In individuals aged 16 to 64, VE of primary vaccination within 90 days was 35.6% (95% CI, 19.0–48.8%). After booster, VE increased to 68.7% (60.6–75.1%). In individuals aged ≥65, VE of primary and booster was 31.2% (−44.0–67.1%) and 76.5% (46.7–89.7%), respectively. Relative VE of booster compared with primary vaccination was 52.9% (41.0–62.5%) in individuals aged 16 to 64 and 65.9% (35.7–81.9%) in individuals aged ≥65. Conclusions During BA.1 and BA.2 epidemic in Japan, mRNA COVID-19 primary vaccination provided modest protection. Booster vaccination was necessary to protect against symptomatic infections.http://dx.doi.org/10.1080/14760584.2023.2188950ba.1ba.2covid19japanomicronsarscov2vaccine effectiveness |
| spellingShingle | Haruka Maeda Nobuo Saito Ataru Igarashi Masayuki Ishida Mayumi Terada Takayasu Ito Hideko Ikeda Hiroshi Kamura Iori Motohashi Yuya Kimura Masaru Komino Hiromi Arai Osamu Kuwamitsu Nobuhiro Akuzawa Eiichiro Sando Toru Morikawa Haruki Imura Hiroki Inoue Tomoichiro Hayakawa Osamu Teshigahara Yasuji Ohara Motoi Suzuki Konosuke Morimoto Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) Expert Review of Vaccines ba.1 ba.2 covid19 japan omicron sarscov2 vaccine effectiveness |
| title | Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) |
| title_full | Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) |
| title_fullStr | Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) |
| title_full_unstemmed | Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) |
| title_short | Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) |
| title_sort | effectiveness of mrna covid 19 vaccines against symptomatic sars cov 2 infections during the sars cov 2 omicron ba 1 and ba 2 epidemic in japan vaccine effectiveness real time surveillance for sars cov 2 versus |
| topic | ba.1 ba.2 covid19 japan omicron sarscov2 vaccine effectiveness |
| url | http://dx.doi.org/10.1080/14760584.2023.2188950 |
| work_keys_str_mv | AT harukamaeda effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT nobuosaito effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT ataruigarashi effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT masayukiishida effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT mayumiterada effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT takayasuito effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT hidekoikeda effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT hiroshikamura effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT iorimotohashi effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT yuyakimura effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT masarukomino effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT hiromiarai effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT osamukuwamitsu effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT nobuhiroakuzawa effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT eiichirosando effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT torumorikawa effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT harukiimura effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT hirokiinoue effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT tomoichirohayakawa effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT osamuteshigahara effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT yasujiohara effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT motoisuzuki effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT konosukemorimoto effectivenessofmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsduringthesarscov2omicronba1andba2epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus |